对于PCSK9降解的双特异性阿巴LYTAC:对于胆固醇调节的一个有希望的策略
Shuaishuai Cui1, Mingjie Li2, Xiangjun Li2
1School of Chemical Sciences, University of Chinese Academy of Sciences, Beijing 100049, PR China; Central Laboratory, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan 030001, Shanxi, China.
Bioorganic chemistry
|February 18, 2026
概括
我们开发了一种新型的DNA吸收体结构,该结构针对PCSK9 (proprotein convertase subtilisin/kexin type 9) 进行 lysosomal 降解. 这种方法提高了LDL受体的可用性,为治疗心血管疾病 (CVD) 提供了新的策略.
科学领域:
- 生物化学和分子生物学
- 心血管疾病治疗方法 治疗方法
- 药物输送系统 药物输送系统
背景情况:
- 蛋白转化酶亚素/素9型 (PCSK9) 是低密度脂蛋白受体 (LDLR) 周转的关键调节者.
- 抑制PCSK9是心血管疾病 (CVD) 的一个成熟的治疗策略.
- 目前的疗法通常涉及抗体,需要探索替代的非抗体方法.
研究的目的:
- 开发一种基于双特异性DNA吸收体的新型 lysosome-targeting chimera (PCSK9-LYTAC),用于细胞外PCSK9降解.
- 研究PCSK9-LYTAC在促进 lysosomal贩运和恢复LDL吸收方面的疗效.
- 评估PCSK9-LYTAC作为一种模块化,非抗体的策略,用于管理失脂症和心血管疾病.
主要方法:
- 设计和合成一种针对PCSK9的双特异性DNA吸收体结构,并利用溶酶体向机制.
- 在实验室中对HepG2细胞中的PCSK9-LYTAC进行评估,以评估溶酶体局部化和细胞外蛋白质降解.
- 测量细胞表面的LDL吸收和LDLR可用性,以确定功能性救援.
主要成果:
- PCSK9-LYTAC在HepG2细胞中显示出有效的溶酶体局部化.
- 该结构显著恢复了LDL吸收 (大约22%的恢复),表现优于单价性亚体.
- 功能性救援与由于PCSK9降解而增加的LDLR可用性有关.
结论:
- 基于aptamer的LYTACs代表了一种可行的,模块化的,非抗体策略,用于调节细胞外蛋白质平衡.
- PCSK9-LYTAC有效地通过溶酶体贩运促进细胞外PCSK9降解.
- 这种方法对治疗失脂症和心血管疾病的治疗干预具有显著的潜力.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.5K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.5K
Pharmacogenomics: Identification of New Drug Targets
25
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
25
Transducer Mechanism: Enzyme-Linked Receptors
4.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
4.3K


